Autolus Therapeutics announces new data on obe-cel for B-ALL patients with extramedullary disease, showing promising response rates.
Quiver AI Summary
Autolus Therapeutics plc has announced the online publication of an abstract detailing data on its programmed T cell therapy, obe-cel, aimed at treating patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and extramedullary disease (EMD). The analysis will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 to June 2, 2026. Results from the Phase Ib/II FELIX study indicate that obe-cel has an overall response rate of 59% among patients with EMD, with a median duration of response of 42.6 months, suggesting its potential as a treatment for this challenging patient group. The study highlights favorable response and safety outcomes for obe-cel, especially for those with adverse risk factors. Autolus continues to focus on developing innovative T cell therapies for cancer and autoimmune diseases.
Potential Positives
- The upcoming presentation at the ASCO Annual Meeting highlights the efficacy of obe-cel in treating difficult-to-treat patients with extramedullary disease (EMD), which may enhance the company's visibility in the oncology community.
- The reported overall response rate of 59% and a median duration of response of 42.6 months for obe-cel in patients with EMD suggests a strong therapeutic potential, indicating that the product may fill a significant treatment gap in relapsed/refractory B-ALL.
- The findings suggest a positive benefit-risk profile for obe-cel, particularly for patients with adverse risk features, which could strengthen regulatory and prescribing confidence among healthcare professionals.
- This press release underscores Autolus' commitment to developing innovative therapies, positioning the company favorably within the competitive landscape of biopharmaceuticals focused on cancer treatment.
Potential Negatives
- There may be concerns about the efficacy of obe-cel for patients with extramedullary disease (EMD), as the overall remission rate is 59%, which some may perceive as insufficient for a challenging condition.
- The reliance on a post-hoc analysis in the Phase Ib/II FELIX study could raise questions about the robustness and validity of the findings being presented at ASCO.
- The complexity of treatment with a tumor burden-guided dosing strategy to minimize toxicity may indicate potential difficulties in standardizing care for patients.
FAQ
What is the focus of Autolus Therapeutics' latest ASCO abstract?
The abstract highlights the use of obe-cel for patients with relapsed/refractory B-ALL and extramedullary disease.
When and where will the ASCO Annual Meeting take place?
The ASCO Annual Meeting is scheduled for May 29 – June 2, 2026, in Chicago, Illinois.
What are the findings related to obe-cel in the FELIX study?
The FELIX study found an overall response rate of 59% and a median duration of response of 42.6 months for patients with extramedullary disease.
Who will present the findings of the abstract at ASCO?
The findings will be presented by Jae Park, MD, from Memorial Sloan Kettering Cancer Center.
What is Autolus Therapeutics' mission?
Autolus Therapeutics develops next-generation T cell therapies for treating cancer and autoimmune diseases using proprietary technologies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AUTL Hedge Fund Activity
We have seen 36 institutional investors add shares of $AUTL stock to their portfolio, and 54 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MAK CAPITAL ONE LLC added 3,616,144 shares (+12.1%) to their portfolio in Q1 2026, for an estimated $4,990,278
- DEEP TRACK CAPITAL, LP removed 2,568,613 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $5,111,539
- BLACKROCK, INC. removed 2,205,093 shares (-59.8%) from their portfolio in Q1 2026, for an estimated $3,043,028
- ACADIAN ASSET MANAGEMENT LLC removed 1,776,520 shares (-98.5%) from their portfolio in Q1 2026, for an estimated $2,451,597
- AFFINITY ASSET ADVISORS, LLC removed 1,750,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,482,500
- ARMISTICE CAPITAL, LLC removed 1,700,000 shares (-9.7%) from their portfolio in Q1 2026, for an estimated $2,346,000
- ATLE FUND MANAGEMENT AB removed 1,169,634 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,614,094
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$AUTL Analyst Ratings
Wall Street analysts have issued reports on $AUTL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 01/12/2026
To track analyst ratings and price targets for $AUTL, check out Quiver Quantitative's $AUTL forecast page.
$AUTL Price Targets
Multiple analysts have issued price targets for $AUTL recently. We have seen 3 analysts offer price targets for $AUTL in the last 6 months, with a median target of $10.0.
Here are some recent targets:
- Emily Bodnar from HC Wainwright & Co. set a target price of $10.0 on 05/14/2026
- Gil Blum from Needham set a target price of $10.0 on 04/09/2026
- Salim Syed from Mizuho set a target price of $10.0 on 03/31/2026
Full Release
LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.
“Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival compared to marrow-only relapse. With an overall response rate of 59% and a median duration of response (mDOR) of 42.6 months for patients with EMD, obe-cel may be considered as a potential treatment option for this difficult to treat population of patients,” said Matthias Will, MD, Autolus Chief Development Officer.
Abstract 6517
Title
: The effect of obecabtagene autoleucel (obe-cel) on adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and extramedullary disease (EMD).
Session Type and Track:
Rapid Oral Abstract: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant.
Session Date and Time
: May 30, 2026; 1:15 – 2:45PM CDT
Session Room
: E450a
Abstract Number
: 6517
Presentation time:
2:27 – 2:33pm CDT
Presenting Author
: Jae Park, MD, Director, Adult ALL Program | Acting Chief, Cellular Therapeutics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Summary: A post-hoc analysis of the Phase Ib/II FELIX study (NCT04404660) was conducted, evaluating the efficacy and safety of obe-cel in patients with relapsed or refractory (r/r) B-ALL, by EMD status at lymphodepletion (LD). Following LD, adults with r/r B-ALL received obe-cel using a tumor burden-guided dosing strategy to minimize toxicity. Obe-cel treatment demonstrated favorable response and safety outcomes in patients with and without EMD in the FELIX trial. Of 127 obe-cel infused patients, 27 (21%) had EMD at LD. Among responders, duration of response in patients with EMD was 42.6 months, and the overall remission rate was 59%. Overall, these findings suggest a positive benefit–risk profile for obe-cel, including for patients with adverse risk features, specifically EMD at LD.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit
www.autolus.com
.
Contact:
Amanda Cray
+1 617-967-0207
[email protected]
